Virgo-Meds review

Virgo-Meds describes an online clinical assessment followed, when appropriate, by a prescription and pharmacy delivery. Its September 2, 2026 terms name OpenLoop Health and affiliated medical groups, including OpenLoop Healthcare Partners, PC, in the service arrangement. The platform itself says it does not provide medical services.

The homepage names Robert M. Korolevich as a medical adviser and separately says prescribing decisions belong to the clinician reviewing the assessment. An adviser’s biography does not tell a patient who will prescribe or establish that individual’s licensing for the patient’s state. Ask for the treating clinician and dispensing pharmacy rather than relying on the adviser’s title.

The homepage and FAQ say the plan covers the clinician, labs, medication, delivery and care-team support. The weight-loss page adds messaging, video visits and provider-directed dose adjustments. Those are useful inclusions to verify against the eventual quote.

The current public pages reviewed do not establish a numeric semaglutide or tirzepatide price. They say the amount depends on the recommended program and will be disclosed before payment. A $50 promotional code appears in the site banner, but without a base price and eligibility conditions it does not establish the treatment cost. Request the regular charge, any first-order discount and the renewal interval together.

Virgo-Meds says medication ships every four weeks in discreet packaging, with no separate shipping charge in the advertised bundle. The homepage outlines assessment, clinician review and dispatch as stages, but those promotional timelines are not a guaranteed delivery date.

Its price description uses monthly language while the shipping schedule uses four weeks. Confirm whether billing follows a calendar month, a 28-day cycle or a prepaid term. Also ask whether labs means all required testing or a specified panel, and how an unexpected shipment delay affects the next charge.

The FAQ says cancellation must be requested at least 72 hours before the next billing date and promises a full refund if a clinician declines treatment. Those claims address future renewal and clinical rejection; they do not establish a right to return a filled prescription.

The public refund-policy page is a generic retail template referring to unused items with tags and an unfilled return-address placeholder. It does not provide a reliable medication-specific return procedure. Before paying, obtain the actual prescription cancellation and refund terms and the contact for a damaged, incorrect or missing shipment. Do not assume the template’s thirty-day return window applies to dispensed medication.

The homepage and FAQ advertise all fifty states plus D.C., while the footer says treatment is not available in all fifty states. The legal terms clarify that medication and therapy availability varies by state and clinical appropriateness. The FAQ also lists states where an initial video visit is required. Confirm the exact product and visit format for where you will be located.

The offered semaglutide tablet is described as dissolvable, alongside compounded injections and low-dose programs. These are not interchangeable with approved branded medicines. Compounded drugs are not FDA-approved, and published benefits for an approved medication do not establish equivalent results for a different formulation or dosing schedule.

Readers who value messaging, optional video access and an advertised lab-inclusive bundle may find the service worth investigating. Existing GLP-1 patients are told a clinician may review their current prescription, but continued dosing is not guaranteed.

The next useful step is obtaining a complete quote and clear medication terms—not assuming a promotional banner establishes value. Confirm the prescriber, pharmacy, state eligibility, recurring price and refund rules. Those details would make the bundle comparable with a provider that publishes a complete price menu.